Free Trial
TSE:BHC

Bausch Health Companies 8/3/2023 Earnings Report

Bausch Health Companies logo
C$7.47 +0.16 (+2.19%)
As of 05/2/2025 04:00 PM Eastern

Bausch Health Companies EPS Results

Actual EPS
C$1.08
Consensus EPS
C$1.00
Beat/Miss
Beat by +C$0.08
One Year Ago EPS
N/A

Bausch Health Companies Revenue Results

Actual Revenue
$2.91 billion
Expected Revenue
$2.74 billion
Beat/Miss
Beat by +$169.79 million
YoY Revenue Growth
N/A

Bausch Health Companies Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Bausch Health Companies Earnings Headlines

Bausch Health Companies (BHC) Gets a Hold from RBC Capital
Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
See More Bausch Health Companies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bausch Health Companies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bausch Health Companies and other key companies, straight to your email.

About Bausch Health Companies

Bausch Health Companies (TSE:BHC) operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

View Bausch Health Companies Profile

More Earnings Resources from MarketBeat